This weekly update in Vaccines Research highlights recent regulatory actions, clinical development progress, early-stage data releases, and global partnerships shaping the field.
In Today’s Newsletter
Dive deeper
💊 Scancell iSCIB1+ gains FDA Fast Track, updates Phase 2 melanoma data [1]
https://scancell.co.uk/wp-content/uploads/2026/04/Scancell-Receives-FDA-Fast-Track-Designation-Press-Release.pdf
Context: iSCIB1+ (Scancell; DNA immunotherapy) in Phase 2 SCOPE with ipilimumab + nivolumab; PFS data maturing.
Key point: FDA grants Fast Track; Phase 2 shows improved progression-free survival vs ipilimumab + nivolumab alone.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 Anixa secures Mexican patent for breast cancer vaccine [2]
https://ir.anixa.com/press-releases/detail/1122/anixa-biosciences-announces-issuance-of-mexican-patent
Context: Vaccine (Anixa + Cleveland Clinic) targets alpha-lactalbumin; Phase 1 completed (safety and immune response).
Key point: Mexican Patent No. 432748 extends protection to 2040, supporting global IP strategy.
Implication: Signals pipeline investment and modality expansion.
🦠 Tonix advances TNX-4800 Lyme prevention program [3]
https://ir.tonixpharma.com/news-events/press-releases/detail/1624/tonix-pharmaceuticals-announces-presentation-of-phase-1
Context: TNX-4800 (Tonix; anti-OspA monoclonal antibody) shows Phase 1 data; targets Borrelia burgdorferi.
Key point: Company plans adaptive, placebo-controlled Phase 2 field study; FDA interaction scheduled.
Implication: May influence prescriber choice and payer reviews pending full data.
🌏 KM Biologics, Serum Institute partner on JE vaccine scale-up [4]
https://www.seruminstitute.com/KM_Biologics_Co_Ltd_Enters_into_a_Technology_Collaboration_with_Serum_Institute_Of_India.php
Context: Technology transfer for Japanese encephalitis vaccine; SII to begin development in India.
Key point: Collaboration focuses on manufacturing scale and supply for national immunization needs.
Implication: May expand screening, initiation, and follow-up at scale.
🧪 Oxford, SII licence next-gen malaria vaccine R78C [5]
https://www.seruminstitute.com/University_of_Oxford_and_SII_Agree_Licence_to_Advance_the_Next-Generation_Multi-Stage_Malaria_Vaccine_Candidate_Component_R78C.php
Context: R78C combines RIPR and CyPRA antigens; builds on Oxford–SII malaria collaboration.
Key point: Non-exclusive licence enables development, manufacturing, and potential commercialization.
Implication: Signals pipeline investment and modality expansion.
💉 CARB-X funds AdJane gonorrhea vaccine program [6]
https://adjane.com/news/hello-world-3/
Context: AdJane uses outer membrane vesicle platform; Phase 1 safety established.
Key point: CARB-X awards $2.6M to advance candidate targeting Neisseria gonorrhoeae.
Implication: Signals pipeline investment and modality expansion.
Why it matters
- Immuno-oncology combinations continue to evolve, with Scancell positioning iSCIB1+ against established checkpoint regimens.
- Vaccine innovation spans cancer, infectious disease, and AMR, reflecting broad modality momentum.
- Manufacturing and licensing deals (SII, KM Biologics, Oxford) emphasize global access and scale, especially in LMICs.
- Passive immunization strategies (Tonix) highlight alternatives where vaccines face uptake or timing challenges.
- CARB-X funding reinforces urgency around antimicrobial resistance and STI prevention.
🎯 Catch up on the Top Vaccine news from the past two weeks, curated by the LucidQuest team.
📚 View the full Vaccines archive on our research hub page.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
FAQ
What does FDA Fast Track mean for iSCIB1+ (Scancell)?
Fast Track enables more frequent FDA interaction and eligibility for expedited pathways such as Priority Review or Accelerated Approval. It may streamline development timelines if data remain supportive [1].
What is unique about Anixa’s breast cancer vaccine approach?
It targets alpha-lactalbumin, a “retired protein” linked to lactation but expressed in some tumors, aiming to direct immune responses without harming normal tissue (mechanistic detail per source) [2].
How does TNX-4800 differ from Lyme vaccines?
TNX-4800 is a monoclonal antibody providing passive immunity, which may act quickly after dosing, unlike vaccines that require time to generate protection (timing details per source) [3].
Why is the KM Biologics–SII collaboration important?
It focuses on scaling production of Japanese encephalitis vaccine in India, supporting national immunization supply and broader regional access [4].
What is R78C in malaria prevention?
R78C is a next-generation candidate combining multiple parasite antigens to target different lifecycle stages, with the aim of improving efficacy and durability (specific endpoints not stated) [5].
What role does CARB-X play in AdJane’s program?
CARB-X provides non-dilutive funding and requires stewardship and access planning, supporting development of interventions that may reduce antimicrobial resistance [6].
Entities / Keywords
Scancell (iSCIB1+, SCOPE, melanoma), Anixa Biosciences (alpha-lactalbumin vaccine), Tonix Pharmaceuticals (TNX-4800, OspA, Lyme), KM Biologics, Serum Institute of India (SII), Japanese encephalitis vaccine, University of Oxford (R78C, malaria), CARB-X, AdJane (gonorrhea vaccine, OMV platform), Neisseria gonorrhoeae
References